Urological Oncology at Fudan University Shanghai Cancer Center | CMCS

Expert Urological Cancer Surgery & Treatment in Shanghai

The Department of Urological Oncology at Fudan University Shanghai Cancer Center (FUSCC) is one of China's most distinguished centers for the surgical and multidisciplinary management of urological cancers, with a national reputation for excellence in prostate cancer, bladder cancer, kidney cancer, and testicular cancer. As a dedicated cancer center, FUSCC's urological oncology program offers a uniquely focused approach to urological malignancies — combining high-volume surgical expertise with precision oncology, immunotherapy, and access to clinical trials — that distinguishes it from general hospital urology departments.

For international patients with urological cancer — whether seeking surgical treatment, a second opinion, access to novel targeted therapies or immunotherapy, or expert management of advanced or castration-resistant prostate cancer — FUSCC's urological oncology department offers an unparalleled combination of oncological expertise and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at FUSCC.

About the Department

FUSCC's urological oncology department is a national key clinical specialty performing hundreds of urological cancer operations annually. The department operates dedicated urological oncology wards, a comprehensive outpatient urological oncology clinic, a urological cancer MDT, a robotic and minimally invasive surgical program, and works in close collaboration with medical oncology, radiation oncology, pathology, and molecular diagnostics through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading urology and oncology journals including European Urology, Journal of Clinical Oncology, Journal of Urology, Annals of Oncology, and BJU International.

Conditions Treated

Prostate Cancer

• Localized Prostate Cancer (Low Risk) — Active surveillance with PSA, MRI, and biopsy monitoring; radical prostatectomy for patients preferring definitive treatment; radiation therapy coordination
• Localized Prostate Cancer (Intermediate/High Risk) — Robotic-assisted radical prostatectomy (RARP) with nerve-sparing technique; extended pelvic lymph node dissection; adjuvant or salvage radiation therapy; adjuvant ADT for high-risk features
• Locally Advanced Prostate Cancer — Multimodal treatment; long-term ADT + radiation therapy; surgical resection for selected cases
• Biochemical Recurrence after Radical Prostatectomy — PSMA PET-CT for recurrence localization; salvage radiation therapy; ADT; enzalutamide/apalutamide for nmCRPC
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — ADT + docetaxel; ADT + abiraterone; ADT + enzalutamide; ADT + apalutamide; ADT + darolutamide; triplet therapy (ADT + docetaxel + darolutamide)
• Non-Metastatic CRPC (nmCRPC) — Enzalutamide, apalutamide, darolutamide
• Metastatic CRPC (mCRPC) — Abiraterone + prednisone; enzalutamide; cabazitaxel; olaparib/rucaparib for HRR-mutated; pembrolizumab for MSI-H; lutetium-177 PSMA-617 (Pluvicto) for PSMA-positive mCRPC; radium-223 for bone-predominant disease
• BRCA1/2-Mutated Prostate Cancer — Olaparib and rucaparib; germline testing and family counseling

Bladder Cancer

• Non-Muscle-Invasive Bladder Cancer (NMIBC) — TURBT with blue light cystoscopy; intravesical BCG for high-risk NMIBC; intravesical chemotherapy (mitomycin C, gemcitabine); nadofaragene firadenovec for BCG-unresponsive CIS; pembrolizumab for BCG-unresponsive NMIBC
• Muscle-Invasive Bladder Cancer (MIBC) — Neoadjuvant cisplatin-based chemotherapy (ddMVAC, GC); robotic radical cystectomy with intracorporeal neobladder or ileal conduit; bladder preservation with trimodality therapy (TURBT + chemoradiation) for selected patients
• Advanced/Metastatic Urothelial Carcinoma — Gemcitabine + cisplatin or carboplatin; pembrolizumab maintenance after platinum-based chemotherapy (JAVELIN Bladder 100); enfortumab vedotin + pembrolizumab (EV-302); sacituzumab govitecan; erdafitinib for FGFR-altered disease; avelumab maintenance
• Upper Tract Urothelial Carcinoma — Radical nephroureterectomy; adjuvant nivolumab; erdafitinib for FGFR-altered disease

Kidney Cancer (Renal Cell Carcinoma)

• Localized RCC — Robotic partial nephrectomy for nephron-sparing surgery (T1-T2); radical nephrectomy for larger tumors; ablative therapies (RFA, cryoablation) for small renal masses in poor surgical candidates; active surveillance for very small renal masses
• Locally Advanced RCC — Radical nephrectomy with lymph node dissection; adjuvant pembrolizumab for high-risk resected RCC
• Metastatic RCC (Clear Cell) — Nivolumab + ipilimumab (IMDC intermediate/poor risk); pembrolizumab + axitinib; nivolumab + cabozantinib; lenvatinib + pembrolizumab; cabozantinib; sunitinib; pazopanib; belzutifan for VHL-associated RCC; nivolumab monotherapy second-line
• Non-Clear Cell RCC — Papillary RCC (savolitinib for MET-driven); chromophobe RCC; collecting duct carcinoma; clinical trials
• Hereditary RCC — VHL disease, hereditary papillary RCC, HLRCC, SDH-deficient RCC; genetic counseling and surveillance

Testicular Cancer

• Stage I Seminoma — Radical orchiectomy; active surveillance; adjuvant carboplatin or radiation for selected patients
• Stage I Non-Seminoma — Radical orchiectomy; active surveillance; nerve-sparing RPLND; adjuvant BEP
• Metastatic Germ Cell Tumors — BEP chemotherapy; VIP for intermediate/poor risk; post-chemotherapy RPLND for residual masses; salvage TIP or VeIP; high-dose chemotherapy with autologous stem cell rescue for relapsed disease

Penile & Adrenal Cancer

• Penile Cancer — Organ-sparing surgery; partial/total penectomy; inguinal lymph node dissection; pembrolizumab for advanced disease
• Adrenal Cortical Carcinoma — Laparoscopic and robotic adrenalectomy; mitotane therapy; EDP-M chemotherapy
• Pheochromocytoma & Paraganglioma — Laparoscopic adrenalectomy; alpha-blockade; SDH mutation testing

Robotic & Minimally Invasive Urological Oncology Surgery

FUSCC's urological oncology department offers the full range of robotic and minimally invasive surgical approaches:

• Robotic-Assisted Radical Prostatectomy (RARP) — Nerve-sparing technique for potency preservation; extended pelvic lymph node dissection; one of Shanghai's most experienced RARP programs
• Robotic Partial Nephrectomy — Nephron-sparing surgery with zero ischemia techniques; off-clamp resection for renal function preservation
• Robotic Radical Cystectomy — Intracorporeal neobladder and ileal conduit construction; reduced blood loss and faster recovery
• Robotic Retroperitoneal Lymph Node Dissection (RPLND) — For testicular cancer staging and post-chemotherapy residual mass resection
• Robotic Adrenalectomy — For adrenal tumors including pheochromocytoma
• Blue Light Cystoscopy — Hexaminolevulinate (HAL)-enhanced cystoscopy for improved NMIBC detection and resection

Lutetium-177 PSMA Therapy for Prostate Cancer

FUSCC offers lutetium-177 PSMA-617 (Pluvicto) — a targeted radioligand therapy that delivers beta radiation directly to PSMA-expressing prostate cancer cells — for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed after androgen receptor pathway inhibitors and taxane chemotherapy. This precision nuclear medicine therapy, approved based on the landmark VISION trial, offers meaningful improvements in progression-free and overall survival for eligible patients.

Urological Cancer MDT

All urological cancer cases at FUSCC are reviewed by the urological cancer MDT, integrating urological oncological, medical oncological, radiation oncological, radiological, nuclear medicine, and pathological expertise. The MDT's precision oncology approach includes:

• PSMA PET-CT — For prostate cancer staging, biochemical recurrence localization, and Lu-177 PSMA eligibility assessment
• HRR Gene Testing — Germline and somatic BRCA1/2, ATM, CDK12, and other HRR gene testing for PARP inhibitor eligibility in prostate cancer
• FGFR Alteration Testing — For erdafitinib eligibility in urothelial cancer
• PD-L1 & MSI Testing — For immunotherapy eligibility across urological cancers
• VHL & MET Testing — For belzutifan and savolitinib eligibility in RCC
• Comprehensive NGS — For identification of rare actionable alterations and clinical trial eligibility

Why International Patients Choose FUSCC Urological Oncology

• Dedicated Cancer Center Focus — Pure oncological expertise without the competing priorities of a general urology department
• Robotic Surgery Expertise — High-volume robotic prostatectomy, partial nephrectomy, and cystectomy program
• Lu-177 PSMA Therapy — Access to lutetium-177 PSMA-617 for eligible mCRPC patients
• Novel Therapy Access — EV + pembrolizumab, belzutifan, darolutamide triplet, and other novel agents
• Clinical Trial Access — Active participation in trials for novel urological cancer therapies
• Cost-Effectiveness — World-class urological cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your urological cancer diagnosis, PSA results, imaging (CT, MRI, PSMA PET-CT), biopsy reports, molecular profiling, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate urological oncologist based on your tumor type — prostate, bladder, kidney, or testicular cancer.
4. MDT Submission — Where appropriate, we facilitate pre-arrival case review by FUSCC's urological cancer MDT.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near FUSCC, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of molecular profiling, imaging, surgical admission, or systemic therapy scheduling.
8. Post-Treatment Follow-Up — Pathology and molecular profiling report translation, treatment plan interpretation, and remote follow-up after you return home.

Book a Consultation

If you are seeking expert urological cancer care in Shanghai — whether for prostate cancer, bladder cancer, kidney cancer, testicular cancer, or a second opinion on a urological cancer diagnosis — CMCS can arrange a specialist consultation with FUSCC's urological oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com